Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-09-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-021-00355-5 |
id |
doaj-7a5bb3f3059146f4bb5221529e84bf10 |
---|---|
record_format |
Article |
spelling |
doaj-7a5bb3f3059146f4bb5221529e84bf102021-09-12T11:31:03ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202021-09-015111010.1186/s41687-021-00355-5Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumorsChristina Darden0Mark Price1David Ray2Grace Goldstein3Diana Goss4Lee Bennett5Diana Garbinsky6Ramya Thota7Department of Surveys and Observational Studies, RTI Health SolutionsDepartment of Surveys and Observational Studies, RTI Health SolutionsIpsen Biopharmaceuticals, Inc.Carcinoid Cancer FoundationDepartment of Patient-Reported Outcomes, RTI Health SolutionsDepartment of Biometrics, RTI Health SolutionsDepartment of Biometrics, RTI Health SolutionsIntermountain Medical CenterAbstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receiving LA SSA injections. Methods We conducted a serial survey, informed by qualitative interviews with eight patients treated with LA SSAs and two nurses who administer LA SSA injections, among patients undergoing LA SSA treatment over a 28-day period (administered at baseline and 14 days and 28 days after injection). Eligible patients, recruited by the Carcinoid Cancer Foundation, self-reported having received an LA SSA injection for physician-diagnosed NET within the 5 days before the survey. Results 202 patients completed the survey at baseline (82 receiving lanreotide and 120 receiving octreotide), 148 at day 14, and 124 at day 28. Patients reported consistently high satisfaction levels with their most recent LA SSA injection (91.1% at baseline, 85.1% at day 14, and 85.5% at day 28); 68.8% reported that their injection experience differed based on the nursing staff administering the injection. Conclusions Satisfaction with LA SSA injections is high among patients in this population, and specific experiences with LA SSA injections varied based on the nursing staff administering the injection. Evaluations of patients’ experiences and satisfaction with treatment are increasingly important as patients take more active roles in decision-making for their treatment pathways.https://doi.org/10.1186/s41687-021-00355-5Neuroendocrine tumorSerial surveyPatient experienceSatisfactionInterviewsSomatostatin analog |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christina Darden Mark Price David Ray Grace Goldstein Diana Goss Lee Bennett Diana Garbinsky Ramya Thota |
spellingShingle |
Christina Darden Mark Price David Ray Grace Goldstein Diana Goss Lee Bennett Diana Garbinsky Ramya Thota Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors Journal of Patient-Reported Outcomes Neuroendocrine tumor Serial survey Patient experience Satisfaction Interviews Somatostatin analog |
author_facet |
Christina Darden Mark Price David Ray Grace Goldstein Diana Goss Lee Bennett Diana Garbinsky Ramya Thota |
author_sort |
Christina Darden |
title |
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
title_short |
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
title_full |
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
title_fullStr |
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
title_full_unstemmed |
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
title_sort |
patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors |
publisher |
SpringerOpen |
series |
Journal of Patient-Reported Outcomes |
issn |
2509-8020 |
publishDate |
2021-09-01 |
description |
Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receiving LA SSA injections. Methods We conducted a serial survey, informed by qualitative interviews with eight patients treated with LA SSAs and two nurses who administer LA SSA injections, among patients undergoing LA SSA treatment over a 28-day period (administered at baseline and 14 days and 28 days after injection). Eligible patients, recruited by the Carcinoid Cancer Foundation, self-reported having received an LA SSA injection for physician-diagnosed NET within the 5 days before the survey. Results 202 patients completed the survey at baseline (82 receiving lanreotide and 120 receiving octreotide), 148 at day 14, and 124 at day 28. Patients reported consistently high satisfaction levels with their most recent LA SSA injection (91.1% at baseline, 85.1% at day 14, and 85.5% at day 28); 68.8% reported that their injection experience differed based on the nursing staff administering the injection. Conclusions Satisfaction with LA SSA injections is high among patients in this population, and specific experiences with LA SSA injections varied based on the nursing staff administering the injection. Evaluations of patients’ experiences and satisfaction with treatment are increasingly important as patients take more active roles in decision-making for their treatment pathways. |
topic |
Neuroendocrine tumor Serial survey Patient experience Satisfaction Interviews Somatostatin analog |
url |
https://doi.org/10.1186/s41687-021-00355-5 |
work_keys_str_mv |
AT christinadarden patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT markprice patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT davidray patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT gracegoldstein patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT dianagoss patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT leebennett patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT dianagarbinsky patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors AT ramyathota patientssatisfactionwithlongactinginjectablesomatostatinanalogtherapyforneuroendocrinetumors |
_version_ |
1717755601284497408 |